Relevant bibliographies by topics / Re-188

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Re-188'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Re-188.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Re-188"

1

Rhodes, B. A., C. R. Lambert, M. J. Marek, F. F. Knapp, and E. B. Harvey. "Re-188 labelled antibodies." Applied Radiation and Isotopes 47, no. 1 (January 1996): 7–14. http://dx.doi.org/10.1016/0969-8043(95)00262-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Argyrou, Maria, Alexia Valassi, Maria Andreou, and Maria Lyra. "Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy." International Journal of Molecular Imaging 2013 (April 9, 2013): 1–7. http://dx.doi.org/10.1155/2013/290750.

Full text
Abstract:
Rhenium-188 (Re-188) is a high energy -emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy -emission, which could be detected by -cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the -emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.
APA, Harvard, Vancouver, ISO, and other styles
3

Tishchenko, V. K., V. M. Petriev, O. P. Vlasova, and E. D. Stepchenkova. "Effect of administration route on the biodistribution of albumin microspheres labelled with Re-188." "Radiation and Risk" Bulletin of the National Radiation and Epidemiological Registry 30, no. 4 (2021): 85–93. http://dx.doi.org/10.21870/0131-3878-2021-30-4-85-93.

Full text
Abstract:
Nowadays the radiolabeled microspheres are established tools for radioembolization of primary and metastatic liver cancer. Human serum albumin microspheres (HSA) are unique carriers for selective and controlled radionuclide delivery to malignant tumors. Rhenium-188 (Re-188), which decays with beta particles (2.12 MeV (71.1%) and 1.965 MeV (25.6%) and gamma emission (155 keV (15.1%)) is one of the most available and promising generator-based radionuclide for cancer therapy. The purpose of this work was to study the biodistribution of microspheres based on hu-man serum albumin labeled with Re-188 (Re-188-HSA) in animals after different routes of admin-istration. The size of more than 95% of microspheres was 10-20 μm. The studies were carried out on outbred white mice and inbred C57BL/6 mice with transplanted Lewis adenocarcinoma after intravenous, intramuscular and intratumoral administration. After intravenous injection the high-est amount of Re-188-HSA in organs and tissues was observed: up to 311.3%/g in lungs, up to 74.30%/g in thyroid gland, up to 12.70%/g in liver, up to 0,81%/g in blood. After the intramuscular injection of 188Re-HSA, the concentration of 188Re-HSA in organs and tissues was significantly lower and did not exceed 1%/g, except for thyroid gland (1,10-17.80%/g). After intratumoral injec-tion the amount of Re-188-HSA in tumor varied from 16.7 to 26.8%/g, that was higher as compared with other organs and tissues. Thus, the routes of Re-188-HSA administration significantly affect its behavior in the body. The obtained results can be used to evaluate the Re-188-HSA potential for radionuclide tumor therapy after intravascular or intratumoral administration.
APA, Harvard, Vancouver, ISO, and other styles
4

Durack, L., J. Eary, J. Vanderheyden, and D. Williams. "GAMMA CAMERA IMAGING OF Re-188 AND Re-186." Clinical Nuclear Medicine 13, Supplement (September 1988): P13. http://dx.doi.org/10.1097/00003072-198809001-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

EARY, J. F., L. DURACK, D. WILLIAMS, and J.-L. VANDERHEYDEN. "Considerations for Imaging Re-188 and Re-186 Isotopes." Clinical Nuclear Medicine 15, no. 12 (December 1990): 911–16. http://dx.doi.org/10.1097/00003072-199012000-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kodina, G. E., A. O. Malysheva, O. Е. Klementyeva, N. A. Taratonenkova, E. A. Lyamtseva, M. V. Zhukova, and A. S. Krasnoperova. "«Synoren, Re-188» – a promising radiopharmaceutical for radiosynovectomy." "Radiation and Risk" Bulletin of the National Radiation and Epidemiological Registry 27, no. 4 (2018): 76–86. http://dx.doi.org/10.21870/0131-3878-2018-27-4-76-86.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Franke, W. G., J. Kropp, R. Koch, R. Runge, R. Hliscs, and K. Liepe. "Comparison of Rhenium-188, Rhenium-186-HEDP and Strontium-89 in palliation of painful bone metastases." Nuklearmedizin 39, no. 06 (2000): 146–51. http://dx.doi.org/10.1055/s-0038-1632262.

Full text
Abstract:
Summary Aim: Several radiopharmaceuticals were compared previously with regard to the efficiency in pain palliation of bone metastases. Furthermore, first results were reported on the suitability for such kind of therapy of the generator produced radionuclide rhenium-188. Method: Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts). These were 16 pts. with Re-188 (2943 ± 609 MBq), 13 pts. with Re-186 (1341 ± 161 MBq) and 15 pts. with Sr-89 (152 ±18 MBq) (6 woman with breast cancer and 38 mens with prostata cancer). Results: 81 of pts. after Re-188,77% after Re-186 and 80 % after Sr-89 reported relief of pain. The Karnofsky-lndex established by pts. increased from 74 ± 9% to 85 ± 11 % after Re-188, from 70 ± 1 1 % to 76 ± 1 1 % after Re-186 and from 62 ± 10% to 69 ± 10% after Sr-89. However, the difference between the pre- and the post-therapeutic value is only statistically significant in the case of Re-188 therapy (p = 0.001 ). A decrease of platelets of 30 ± 14% after 2.8 ± 0.7 for pts. treated with Re-188, of 39 ± 20% after 3.7 ± 1.0 weeks for pts. treated with Re-186 and of 34 ± 26% after 4.4 ± 1.0 weeks for pts. treated with Sr-89 compared to the value before therapy was observed. The difference was not significant between the 3 groups of pts. (p= 0.125 to 0.862). Conclusion: All tried radiopharmaceuticals were effective in pain palliation. The various radionuclides had no significant difference in the pain relief or the bone marrow impairment. If only the Karnofsky-lndex after Re-188 HEDP seems to be a little more increase.
APA, Harvard, Vancouver, ISO, and other styles
8

Edelman, M. J., G. Clamon, D. Kahn, M. Magram, and B. R. Line. "Targeted radiopharmaceutical therapy for advanced lung cancer: Phase I trial of rhenium Re188 somatostatin analogue P2045." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 7672. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7672.

Full text
Abstract:
7672 Background: Both small cell (SCLC) and non-small cell lung cancer (NSCLC) overexpress somatostatin receptors (SSTR). P2045 peptide is an 11-amino acid somatostatin analogue that binds with high affinity to SSTR. The analogue can be labeled with Tc-99m to gauge receptor prevalence, or with Re-188 for 2.1MeV beta radiotherapy. To evaluate the safety of this approach a phase I dose-escalation study of Re-188 P2045 in SSTR positive lung cancer was performed. Methods: Patients (pts) were required to have progressive advanced lung cancer, PS 0–1, and normal organ function. There were no limitations on the number of prior therapies. Tumor SSTR was detected with Tc-99m P2045. If positive, treatment with escalating doses of Re-188 P2045 was instituted. Three doses were evaluated, 30 mCi/m2, 60 mCi/m2 and 90 mCi/m2. A single dose of Re-188 P2045 was allowed. Dose limiting toxicity was defined as ≥ grade 3 non-hematologic toxicity, grade 4 hematologic toxicity or projected renal radiation dose of >20 Gy. Results: 15 pts entered, 7 M, 8 F, median age 61y, 9-PS0, 6 PS1. 13 NSCLC, 2 SCLC. 14 pts had ≥ 2 prior chemotherapy regimens. 1 pt refused standard therapy. All pts were imaged with Tc-99m P2045, 8 pts received Re-188 P2045. The 7 pts who did not proceed to Re-188 P2045 were due to rapid progression (n=2) non-uptake of Tc 99m P2045 (n=2) or projected renal radiation dose above the 20 Gy limit (n=3). All pts treated with Re-188 P2045 (4 at 30 mCi/m2, 3 at 60 mCi/m2 and 1 at 90 mCi/m2) had NSCLC. The major toxicity was grade 1 or 2 lymphopenia. No dose limiting toxicities were seen. All tumors imaged by Tc-99m had uptake of Re- 188. The trial was halted at the 90 mCi/m2 level when 3 pts had projected renal radiation doses above 20Gy. No responses were seen. 5 of the 8 pts (62.5%, 95% CI: 24%, 91%) had stable disease at 8 weeks, all of whom entered with progressive disease.. Median overall survival was 11.5 mo. Conclusions: 1) Re-188 P2045 was well-tolerated. 2) Tc-99m P2045 imaging allows identification of pts who may benefit from Re-188 P2045. 3) While responses were not seen, survival for these heavily pretreated pts is encouraging. 4) Further exploration of this approach utilizing amino acid infusion to ameliorate potential renal toxicity is warranted. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
9

Häfeli, Urs O., William K. Roberts, Dominik S. Meier, Jay P. Ciezki, Gayle J. Pauer, Eric J. Lee, and Martin S. Weinhous. "Dosimetry of a W-188/Re-188 beta line source for endovascular brachytherapy." Medical Physics 27, no. 4 (April 2000): 668–75. http://dx.doi.org/10.1118/1.598928.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dash, Ashutosh, and F. F. (Russ) Knapp Jr. "An overview of radioisotope separation technologies for development of 188W/188Re radionuclide generators providing 188Re to meet future research and clinical demands." RSC Advances 5, no. 49 (2015): 39012–36. http://dx.doi.org/10.1039/c5ra03890a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Re-188"

1

MARCZEWSKI, BARBARA S. "Estudos de marcação do etidronato com sup(188)Re proveniente de diferentes gerações de sup(188)W/sup(188)Re." reponame:Repositório Institucional do IPEN, 2006. http://repositorio.ipen.br:8080/xmlui/handle/123456789/11491.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:52:29Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:01:22Z (GMT). No. of bitstreams: 0
Tese (Doutoramento)
IPEN/T
Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP
APA, Harvard, Vancouver, ISO, and other styles
2

OLIVEIRA, ALEXANDRE de. "Desenvolvimento da tecnologia de preparo de geradores de sup(188)W-sup(188)Re." reponame:Repositório Institucional do IPEN, 2004. http://repositorio.ipen.br:8080/xmlui/handle/123456789/11213.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:49:34Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:02:34Z (GMT). No. of bitstreams: 1 09995.pdf: 3401015 bytes, checksum: aced83202c3f7ecb0a8933fda0aed0aa (MD5)
Dissertacao (Mestrado)
IPEN/D
Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP
APA, Harvard, Vancouver, ISO, and other styles
3

Liang, Qixue. "Development and optimization of W-188/Re-188 and Mo-99/Tc-99m gel radioisotope generators /." free to MU campus, to others for purchase, 1996. http://wwwlib.umi.com/cr/mo/fullcit?p9841211.

Full text
Abstract:
Thesis (Ph. D.)--University of Missouri-Columbia, 1996.
"m in ⁹⁹mTc on short title page is supercript." Typescript. Vita. Includes bibliographical references (leaves 131-136). Also available on the Internet.
APA, Harvard, Vancouver, ISO, and other styles
4

Choudhry, Uzma. "Conjugates of Re-188-DMSA for targeted radionuclide therapy." Thesis, University of Kent, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.409154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

DIAS, CARLA R. de B. R. "Estudo comparativo da marcacao do anticorpo anti-CD20 com sup(188)Re." reponame:Repositório Institucional do IPEN, 2010. http://repositorio.ipen.br:8080/xmlui/handle/123456789/9502.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:27:22Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:06:35Z (GMT). No. of bitstreams: 0
Tese (Doutoramento)
IPEN/T
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
APA, Harvard, Vancouver, ISO, and other styles
6

Brambilla, Tânia de Paula. "Desenvolvimento de métodos para marcação de DMSA pentavalente com 99m Tce 188 Re." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-29062009-160804/.

Full text
Abstract:
Tecnécio-99m é o radionuclídeo mais utilizado em procedimentos para imagem diagnóstica na Medicina Nuclear, mais de 80 % dos radiofármacos são compostos marcados com 99mTc. 99mTc-DMSA(V) tem sido usado no diagnóstico de tumores de tecidos moles, cabeça e pescoço. Este radiofármaco tem uma alta especificidade para detecção de carcinoma medular de tireóide e metástase óssea em vários tipos de cânceres. Estudos de biodistribuição do 188Re-DMSA(V) tem mostrado que suas propriedades farmacocinéticas são similares ao do 99mTc-DMSA(V), então este agente poderia ser usado para terapia desses tumores. O objetivo desse trabalho é o desenvolvimento de métodos para marcação do DMSA(V) com 99mTc e 188Re. O 99mTc-DMSA(V) pode ser preparado por dois métodos. Um dos métodos é o método indireto, que é através do kit comercial de DMSA(III), ajustando-se o pH de 2,5 para ~8,5 com NaHCO3, que foi estudado e otimizado, apresentando bons rendimentos de marcação. O outro é o método direto, pelo preparo de um kit liofilizado de DMSA(V) pronto para marcação com 99mTc, sendo o método de interesse do trabalho pela maior praticidade no uso clínico. A formulação mais adequada do método direto foi: 1,71 mg de DMSA, 0,53 mg de SnCl2.2H2O e 0,83 mg de ácido ascórbico (pH 9). Marcando-se esse kit com 1 a 2 mL de 99mTc, com atividades de até 4736 MBq (128 mCi), e tempo instantâneo de reação, consegue-se rendimento de marcação maior que 95%. O kit liofilizado foi estável por até 6 meses e estudos de biodistribuição confirmaram a qualidade do DMSA (V) marcado com 99mTc usando este kit. O potencial de redução do Re é mais baixo do que do Tc, com isso as condições de preparação do 188Re-DMSA(V) são diferentes das usadas para o 99mTc-DMSA(V). O 188Re-DMSA(V) é preparado em meio ácido, com isso é possível utilizar o kit comercial de DMSA(III) para marcação com 99mTc, que apresenta pH 2,5, na preparação do 188Re- DMSA(V). Com este método conseguiu-se rendimentos de marcação superiores a 95%, com tempo de reação de 30 minutos à 100 ºC, utilizando no máximo 1 mL de 188ReO4 -. Outro método de preparação do 188Re-DMSA(V) também foi estudado, através de um kit líquido contendo 2,5 mg de DMSA, 1,00 mg de SnCl2.2H2O, 30 mg de oxalato de sódio e pH 5. Este kit marcado com 1 mL de 188ReO4 -, com 15 minutos de reação à temperatura ambiente apresentou rendimento de marcação de aproximadamente 91%.
Technetium-99m is the most useful radionuclide in diagnostic imaging procedures in Nuclear Medicine, more than 80 percent of radiopharmaceuticals are 99mTc-labeled compounds. 99mTc-DMSA(V) has been used for imaging of soft tissue, head and neck tumors. It shows a particularly high specificity for medullary thyroid carcinoma and bone metastases in a variety of cancers. Biodistribution studies of 188Re-DMSA(V) have shown that its general pharmacokinetic properties are similar to that of 99mTc-DMSA(V), so this agent could be used for targeted radiotherapy of these tumors. The aim of this work is the development of methods of labeling DMSA(V) with 99mTc and 188Re. 99mTc-DMSA(V) can be prepared by two methods. One of them is the indirect one, through the use of a commercial kit of DMSA (III), by adjusting the pH from 2.5 to ~8.5 with NaHCO3. This method was evaluated and optmized presenting high labeling yields. The other method is the direct one, through the preparation of a liophylised kit ready for labeling with 99mTc, being the method of interest of this work, due to the easy of its clinical use. The most adequate formulation of the kit was: 1.71mg of DMSA, 0.53mg of SnCl2.2H2O and 0.83 mg of ascorbic acid (pH 9). Labeling yields higher than 95% were achieved labeling this kit with 1 to 2 mL of 99mTc with activities up to 4736 MBq (128 mCi). The kit was stable up to 6 months and biodistribution studies confirmed the quality of the DMSA (V) labeled with 99mTc using this kit. The reduction potential of Re is lower than the one for Tc, so the labeling conditions of 188Re-DMSA(V) are diferent from the ones used for 99mTc- DMSA(V). 188Re-DMSA(V) is prepared in acid solution, that makes it possible to use the DMSA (III) comercial kit developed for labeling with 99mTc, prepared in pH 2.5, for labeling with 188Re. Labeling yields higher than 95% were achieved with this methodology, with a rection time of 30 minutes at 100oC using no more than 1 mL of 188ReO4 -. Another method of preparing 188Re-DMSA(V) was also evaluated, using a liquid kit containing 2.5mg of DMSA, 1.00mg of SnCl2.2H2O and 30mg of sodium oxalate at pH 5. This kit was labeled with 1 mL of 188ReO4 -, with 15 minutes of reaction at room temperature resulting in a labeling yield of about 91%.
APA, Harvard, Vancouver, ISO, and other styles
7

BARBEZAN, ANGELICA B. "Comparação da marcação de diversos fosfonatos: MDP, EDTMP e clodronato com sup(188)Re." reponame:Repositório Institucional do IPEN, 2012. http://repositorio.ipen.br:8080/xmlui/handle/123456789/10150.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:35:19Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:08:55Z (GMT). No. of bitstreams: 0
Dissertação (Mestrado)
IPEN/D
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
APA, Harvard, Vancouver, ISO, and other styles
8

LOPES, PAULA R. C. "Estudo de diferentes materiais adsorvedores para o preparo de sistemas geradores de sup(99)Mo-sup(99m)Tc e sup(188)W-sup(188)Re." reponame:Repositório Institucional do IPEN, 2009. http://repositorio.ipen.br:8080/xmlui/handle/123456789/9437.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:26:48Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:06:13Z (GMT). No. of bitstreams: 0
Dissertacao (Mestrado)
IPEN/D
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
APA, Harvard, Vancouver, ISO, and other styles
9

BRAMBILLA, TANIA de P. "Desenvolvimento de metodos para marcacao de DMSA pentavalente com sup(99m)Tc e sup(188)Re." reponame:Repositório Institucional do IPEN, 2009. http://repositorio.ipen.br:8080/xmlui/handle/123456789/11516.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:52:46Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:02:48Z (GMT). No. of bitstreams: 0
Dissertacao (Mestrado)
IPEN/D
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
APA, Harvard, Vancouver, ISO, and other styles
10

Kahmann, Cindy. "Quantifizierung von DNA-Schäden an adhaerenten Zelllinien nach Bestrahlung mit 188 Re- bzw. Röntgenstrahlung unter Zugabe von Methimazol, Nicotinamid und Perchlorat durch den Comet Assay." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2008. http://nbn-resolving.de/urn:nbn:de:bsz:14-ds-1219154119996-02487.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Re-188"

1

Xie, Qingrong. Meiguo di zhuan mai quan tou zi yü 188 jia re men lian suo dian =: Franchise investment and 188 popular chain stores in U.S.A. Burlingame, CA: Jin deng guo ji guang gao chu ban shi ye gong si, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

L, Sastry Shankar M., and Ames Research Center, eds. Influence of high pressure hydrogen environment on creep deformation of Mo-Re, Haynes 188, and NARloy-S alloys: NASA grant no. NAG 2-865, annual technical report. Moffett Field, Calif: National Aeronautics and Space Administration, Ames Research Center, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

L, Sastry Shankar M., and Ames Research Center, eds. Influence of high pressure hydrogen environment on creep deformation of Mo-Re, Haynes 188, and NARloy-S alloys: NASA grant no. NAG 2-865, annual technical report. Moffett Field, Calif: National Aeronautics and Space Administration, Ames Research Center, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Re-188"

1

Sukhoruchkin, S. I., and Z. N. Soroko. "Excited Nuclear States for Re-188 (Rhenium)." In Supplement to I/25 A-G, 2635–38. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-48747-1_421.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sukhoruchkin, S. I., and Z. N. Soroko. "Excited Nuclear States for Re-188 (Rhenium)." In Nuclei with Z = 74 - 103, 755–63. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-30699-0_68.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sukhoruchkin, S. I., and Z. N. Soroko. "Atomic Mass and Nuclear Binding Energy for Re-188 (Rhenium)." In Nuclei with Z = 55 - 100, 5056–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-70609-0_2250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gao, S., and H. J. Zhang. "Monte Carlo Calculation for Initial Activity Uniformity Distributed on a Re-188 Electroplated Aluminum Sheet." In IFMBE Proceedings, 245–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-01697-4_87.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kolesnik, O., and V. Basmanov. "Investigation of Rhenium Complex Formation for Development of Boneseeking Kit for 18 8-W/188-RE Generator." In Radioactive Isotopes in Clinical Medicine and Research XXIII, 403–8. Basel: Birkhäuser Basel, 1999. http://dx.doi.org/10.1007/978-3-0348-8782-3_65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shanabarger, Mickey R. "Comparison of the High Temperature Hydrogen Transport Parameters for the Alloys Incoloy 909, Haynes 188, and Mo-47.5 Re." In Hydrogen Effects in Materials, 243–50. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118803363.ch22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"188. Riccardo I, re d’Inghilterra." In The Baroque Libretto. Toronto: University of Toronto Press, 2011. http://dx.doi.org/10.3138/9781442687219-195.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Decision on Joint Defence Motion on Admissibility of Expert Witnesses/Expert Evidence and Filing of Notice Pursuant to Rule 94bis (B)(i) and (ii), on Re-Filed Defence Request for Disclosure, and on the Joint Defence Motion for Exclusion of Medical Information, Statistics and Abstracts Pertaining to Witnesses TF1-081 and TF1-188, 16 June 2005." In The Law Reports of the Special Court for Sierra Leone (2 vols.), 505–10. Brill | Nijhoff, 2012. http://dx.doi.org/10.1163/9789004223981_055.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Re-188"

1

Balodis, M., J. Bērziņš, Ļ Simonova, V. Bondarenko, T. Krasta, J. Tambergs, A. Jakimovičs, et al. "Structure of the Odd-Odd Nucleus [sup 188]Re." In CAPTURE GAMMA-RAY SPECTROSCOPY AND RELATED TOPICS: Proceedings of the 13th International Symposium on Capture Gamma-Ray Spectroscopy and Related Topics. AIP, 2009. http://dx.doi.org/10.1063/1.3087107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Liang-Cheng, Su-Jung Chen, Chih-Hsien Chang, Te-Wei Lee, and Jui-Hung Shien. "Longitudinally therapeutic evaluation of 188Re-human serum albumin microsphere in hepatoma model by three-dimensional ultrasound imaging: Longitudinally therapeutic evaluation of 188Re-HSAM." In 2015 IEEE International Conference on Imaging Systems and Techniques (IST). IEEE, 2015. http://dx.doi.org/10.1109/ist.2015.7294529.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chang, Ya-Jen, Su-Jung Chen, Chung-Yen Li, Liang-Cheng Chen, Wan-Chi Lee, Chih-Hsien Chang, and Te-Wei Lee. "NanoSPECT/CT imaging and biodistribution of 188Re-HSA microspheres using new radio labeling process in a GP7TB hepatoma rats model (Imaging and Biodistribution of 188Re-HSA microspheres)." In 2015 IEEE International Conference on Imaging Systems and Techniques (IST). IEEE, 2015. http://dx.doi.org/10.1109/ist.2015.7294528.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Eychenne, Romain, Jin-Hui Wang, Claude Picard, Nicolas Lepareur, and Eric Benoist. "Radiopharmaceutcials radiolabelled with 188Re as potential therapeutic tools for hepatocellular carcinoma targeting." In 1st International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2015. http://dx.doi.org/10.3390/ecmc-1-a040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shilova, A., H. Hartmann, R. Runge, and J. Kotzerke. "Untersuchungen zum Nachweis von Einzel- und Doppelstrangbrüchen bei Plasmid-DNA durch Röntgenstrahlung und Re-188 in Kombination mit dem Photosensibilisator ortho-iodoHoechst 33,258." In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708410.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kotzerke, J., K. Tietze, G. Wunderlich, R. Runge, and F. Reissig. "Wirkung der Hypoxie auf die Induktion von Strangbrüchen in Plasmid-DNA durch die Alpha-, Beta- und Auger-Elektronen-Emitter 223 Ra, 188 Re, 99m Tc und DNA-bindendes 99m Tc-Pyren." In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708218.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gwyther, Amy Majsai, and Rebecca Bhatia. "P-172 Development of a process for managing deactivation of ICDs (Implantable Cardiac Defibrillators) and CRT-Ds (Cardiac Re-synchronisation Therapy Defibrillators)." In Finding a Way Forward, Hospice UK National Conference, 22–24 November 2022, Glasgow. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/spcare-2022-hunc.188.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Re-188"

1

Zamora, P. O., H. Bender, H. J. Biersack, and F. F. Jr Knapp. Interim report on intrathoracic radiotherapy of human small-cell lung carcinoma in nude mice with Re-188-RC-160, a radiolabeled somatostatin analogue. Office of Scientific and Technical Information (OSTI), July 1995. http://dx.doi.org/10.2172/87003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Re-188' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography